Story Edition - Immune therapy scores big win against lung cancer in study

 
Show/hide duplicate news articles.
<<10<12345678910>>>10
Timeline loading
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Monday, October 22, 2018

3:18:00 AM CEST

Subscribe
RSS
EMM for iPadEMM for Android

Languages Collapse menu...Expand menu...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
si
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...

Geolocation Information

Place : Alice
Geo Path : Alice,Jim Wells,Texas,United States
lat : 27.74291   lon : -98.068733

Place : Yale
Geo Path : Yale,Crawford,Kansas,United States
lat : 37.483889   lon : -94.641667

Place : New York
Geo Path : New York,Kings,New York,United States
lat : 40.6222   lon : -73.9878

Place : Chicago
Geo Path : Chicago,Cook,Illinois,United States
lat : 41.8265   lon : -87.6413

Place : Shaw
Geo Path : Shaw,St Louis,Minnesota,United States
lat : 47.113333   lon : -92.352778

Quotes... Extracted quotes

Roy Herbst said: "We're not nearly where we need to be yet," External link

fox35orlandoMonday, April 16, 2018 9:35:00 PM CEST

Roger M Perlmutter said: “Our goal is to extend the lives of patients with lung cancer, and the unambiguous survival findings from KEYNOTE-189 showing the risk of death was reduced by half in the KEYTRUDA arm are important not only for patients but also for the medical community,” External link

marketwatchMonday, April 16, 2018 3:35:00 PM CEST

Matthew D Hellmann said: “CheckMate -227 is the first Phase 3 study to demonstrate the important clinical benefit of combining two immunotherapy agents to treat first-line NSCLC patients with high TMB,” External link

4-tradersMonday, April 16, 2018 3:10:00 PM CEST

Roy Herbst said: “When the surgeons open the patients, they see the tumor almost melting away. That is extraordinary,” “It eats it away like a Pac-man. It probably creates a roller coaster of immune response” External link

wrcbtvMonday, April 16, 2018 8:16:00 PM CEST

Patrick Forde said: “Today is a big day in lung cancer,” External link

usaTodayTuesday, April 17, 2018 2:19:00 AM CEST

Roy Herbst told: “I have never seen progress move so fast,” External link

wrcbtvMonday, April 16, 2018 8:16:00 PM CEST

Sabine Maier said: “Lung cancer is a highly complex disease, defined by multiple subtypes, making it increasingly important to define a more precise treatment approach for this disease,” External link

4-tradersMonday, April 16, 2018 3:10:00 PM CEST

Roy Herbst said: “If you want to see long-term survival, you’ve got to give immunotherapy as soon as possible,” “Chemotherapy has limitations. Immunotherapy has the ability to cure. I lead the Yale lung team. We have patients on these immunotherapies alive more than eight years” External link

bostonglobeTuesday, April 17, 2018 3:32:00 AM CEST

Drew Pardoll said: "Given that phase 3 clinical trials are underway, using this neoadjuvant anti-PD-1 drug will likely be practice changing," External link

sciencedailyMonday, April 16, 2018 5:03:00 PM CEST

Leena Gandhi said: “What it suggests is that chemotherapy alone is no longer a standard of care,” External link

HonululuAdvertiserTuesday, April 17, 2018 6:31:00 AM CEST

Leena Gandhi said: “I think we were all surprised at the magnitude of benefit and how clear the difference was at an early analysis, and that we could tell there was an overall survival difference,” External link

HonululuAdvertiserTuesday, April 17, 2018 6:31:00 AM CEST

Drew Pardoll said: "I don’t use the term cure until you survive for 10 years," External link

wrcbtvMonday, April 16, 2018 8:16:00 PM CEST

Matthew Hellmann said: "We have a tool that helps us determine who are the patients that are most likely to benefit from this combination," External link

japantimesTuesday, April 17, 2018 12:04:00 AM CEST

Roy Herbst said: “I’ve been treating lung cancer for 25 years now, and I’ve never seen such a big paradigm shift as we’re seeing with immunotherapy,” External link

bostonglobeTuesday, April 17, 2018 3:32:00 AM CEST

Patrick Forde said: "We wanted to look at the patients' tumor and immune system prior to treatment and examine it again after treatment for changes," External link

sciencedailyMonday, April 16, 2018 5:03:00 PM CEST

Leena Gandhi said: “Immunotherapy is rapidly, in combination with other treatments and on its own, dramatically changing the standard of care for lung cancer,” External link

WashingtonPostTuesday, April 17, 2018 1:38:00 AM CEST

Countries

Subtitles

  • Lung cancer patients can live longer with immune therapy
  • News New hope for turning immune system against cancer?
  • New studies show hope for turning immune system against lung cancer
  • Immune therapy scores big win against lung cancer in study
  • Merck, Bristol-Myers immunotherapies impress in key lung cancer trials
  • Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study
  • Merck and : New Drug Combinations Improve Survival in Lung Cancer
  • Immunotherapy-first cancer treatment a &apos;game-changer&apos;, say scientists
  • Drug reduces size of some lung cancer tumors, relapse rate after surgery

Names

Categories